보고서 요약(국문)

시장 개요
전 세계 포도막염 시장 규모는 2022년 4억 5,600만 달러였으며, 2030년까지 8억 3,700만 달러에 이를 것으로 예상됩니다. 예측 기간(2023~2030년) 동안 연평균 성장률(CAGR)은 4.8%입니다.
포도막염은 안구벽의 중간 조직층에 염증을 일으키는 질환입니다. 대부분의 환자는 20~50세 연령층에 속합니다. 포도막염은 심각한 경우 시력 손실로 이어질 수 있습니다.
시장 동향
전 세계 포도막염 시장 성장을 견인하는 주요 요인은 녹내장성 포도막염, 백내장성 포도막염 등 안과 질환 발병률 증가로 인한 포도막염 관련 수요 증가, 인식 개선 활동 강화, 신약 개발 및 신제품 출시로 이어지는 기술 발전입니다.
제약 회사의 제품 파이프라인 확대와 신약 개발로 이어지는 기술 발전은 시장 성장을 촉진할 것으로 예상됩니다.

포도막염 시장은 기술 발전, 고령 인구 증가, 연구 개발 투자 증가, 녹내장성 포도막염, 백내장성 포도막염, 황반변성(AMD)과 같은 안과 질환 증가, 최신 기술을 활용한 신제품 개발, 그리고 신흥 시장의 의료 인프라 개선에 힘입어 성장하고 있습니다.
포도막염 치료제는 치료 목적으로 널리 사용되고 있습니다. 이러한 치료제의 사용이 증가함에 따라 정부의 지원과 자금 투입도 늘어나고 있습니다. 이러한 자금은 점안액, 주사제, 알약, 임플란트와 같은 포도막염 치료제 생산에 도움이 될 것입니다. 안과 질환 환자 수 증가로 인해 전 세계적으로 포도막염 치료제 시장이 성장하고 있습니다. 또한, 주요 업체들의 기술적으로 진보된 제품 출시도 시장 성장에 중요한 역할을 할 것으로 예상됩니다.
다양한 신제품 출시, 연구 활동, 그리고 포도막염 치료제 관련 인식 제고 활동 또한 시장 성장에 기여하고 있습니다. 예를 들어, 망막 건강 및 더 길고 나은 시력 유지를 목표로 하는 제약 회사인 알리메라 사이언스(Alimera Sciences, Inc.)는 2022년 11월 1일, 아일랜드에 본사를 둔 유럽 자회사인 알리메라 사이언스 유럽(Alimera Sciences Europe Limited)이 유통 파트너인 메디스 제약(Medis Pharmaceutical Company)을 통해 비감염성 포도막염 치료제인 지속 방출형 유리체내 임플란트 ILUVIEN(플루오시놀론 아세토니드 유리체내 임플란트)에 대한 보험 적용 승인을 받았다고 발표했습니다.
치료와 관련된 높은 비용과 부작용 위험은 시장 성장을 저해할 것으로 예상됩니다.
포도막염 치료제 승인에 대한 엄격한 규정은 포도막염 시장 성장을 저해하는 주요 요인입니다. 다양한 요구 사항과 임상 시험을 충족해야 하므로 이러한 약물의 전체 비용이 증가합니다. 이러한 치료와 관련된 높은 비용은 시장 성장을 저해할 가능성이 높습니다.
이러한 약물의 부작용과 관련된 높은 위험 또한 시장 성장을 제한하는 요인입니다. 시장 리콜 또한 시장 성장을 저해하는 주요 요인입니다. 임플란트 누출이나 합병증으로 인해 여러 건의 리콜이 발생하고 있습니다.
COVID-19 영향 분석
코로나19 팬데믹은 전 세계 재정 전망, 운영 및 위기 대응 전략에 부정적인 영향을 미쳤습니다. 특히 COVID-19 발생은 의료 산업에 심각한 타격을 입혔습니다. 포도막염 시장은 COVID-19로 인해 막대한 손실을 입었습니다. 주요 제조업체들은 다양한 연구 및 임상 시험을 시작했습니다. 전 세계적으로 다양한 계획, 제품 출시, 협력 및 합병이 진행되면서 시장 성장을 촉진하고 있습니다. 예를 들어, 2022년 10월 17일 키오라 제약(Kiora Pharmaceuticals, Inc.)은 비감염성 포도막염(안과 염증 질환) 치료제로서의 가능성을 보여주는 KIO-100(이전 PP-001) 1상 연구 결과를 발표했습니다.

세그먼트 분석
전방 포도막염 세그먼트는 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
전방 포도막염 세그먼트는 전 세계 포도막염 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 전 세계 포도막염 시장은 질병 유형에 따라 전방 포도막염, 중간 포도막염, 후방 포도막염, 범포도막염으로 세분화됩니다. 전방 포도막염 세그먼트는 전 세계적으로 발병률 증가, 기술 발전 및 신제품 출시로 인해 가장 큰 시장 점유율을 차지하고 있습니다.
전방 포도막염은 가장 흔한 유형의 포도막염으로, 주로 섬모체와 눈 앞쪽 안쪽(홍채와 각막 사이)에 영향을 미칩니다. 홍채염이라고도 합니다. 전방 포도막염은 눈에 충격을 받거나 이물질이 들어가는 등의 외상으로 인해 발생할 수 있습니다. 또한 매독, 류마티스 관절염, 결핵 및 바이러스성 질환(단순포진)과 같은 일반적인 건강 문제와도 관련이 있습니다. 증상으로는 시야 흐림, 충혈 또는 염증이 있는 눈, 작고 불규칙한 모양의 동공, 빛에 대한 민감성 등이 있습니다.
규제 승인 증가, 기술 발전, 신제품 출시, 연구/임상 시험 진행 등이 시장 성장을 견인하고 있습니다. 예를 들어, 2022년 3월 28일, 바슈앤롬(Bausch + Lomb), 바슈헬스(Bausch Health Companies)의 안과 사업부, 그리고 맥락막상 공간(SCS)을 통해 안구 뒤쪽으로 치료제를 전달하는 방식을 혁신하는 바이오제약 회사인 클리어사이드 바이오메디컬(Clearside Biomedical, Inc.)은 미국에서 XIPERE(트리암시놀론 아세토니드 주사 현탁액)의 상용화를 발표했습니다. 이는 미국 식품의약국(FDA)으로부터 포도막염 관련 황반부종 치료를 위해 맥락막상 사용 승인을 받은 최초의 치료제입니다.
지역 분석
북미는 전 세계 포도막염 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.

북미는 인구 규모, 우수한 의료 인프라, 높은 소득 수준을 바탕으로 전 세계 포도막염 시장을 주도하고 있습니다. 특히 미국의 의료비 지출 증가로 인해 예측 기간 동안 시장 성장세는 비교적 완만할 것으로 예상됩니다. 북미 시장의 상당한 규모는 높은 의료비 지출에 기인합니다.
의료비 지출 증가와 질병에 대한 인식 제고 또한 이 지역 시장 성장에 기여하고 있습니다. 녹내장성 포도막염이나 백내장성 포도막염 등 여러 안과 질환에 대한 치료제 개발, 이 지역의 제약 회사 증가, 정부 승인 확대, 주요 기업들의 존재 또한 포도막염 시장 성장에 영향을 미치고 있습니다.
또한, 신제품 출시 증가도 시장 성장의 주요 요인입니다. 이 지역에서는 다양한 핵심 개발, 기술 발전, 협력 및 계약이 활발하게 이루어지고 있습니다. 예를 들어, 2022년 8월 8일, 맥락막상 공간(SCS)을 통해 안구 뒤쪽으로 치료제를 전달하는 방식을 혁신하는 바이오제약 회사인 클리어사이드 바이오메디컬(Clearside Biomedical, Inc.)은 헬스케어 로열티 파트너스(HealthCare Royalty Partners)와 판매 계약을 체결했다고 발표했습니다.
경쟁 환경
포도막염 시장은 국내외 기업들이 활발하게 경쟁하는 매우 경쟁적인 시장입니다. 노바티스(Novartis Inc.), 애브비(AbbVie), 존슨앤존슨(Johnson & Johnson Services, Inc.), 암젠(Amgen), 알리메라 사이언스(Alimera Sciences), 바슈앤롬(Bausch & Lomb Incorporated), 키오라 파마슈티컬스(Kiora Pharmaceuticals, Inc.), 산텐(Santen Pharmaceutical Co., Ltd.), 아이포인트 파마슈티컬스(EyePoint Pharmaceuticals, Inc.), 클리어사이드 바이오메디컬(Clearside Biomedical) 등이 주요 기업입니다. 이들 기업은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 통해 시장 성장에 기여하고 있습니다. 예를 들어, 망막 건강 및 더 길고 나은 시력 유지를 목표로 하는 제약 회사인 알리메라 사이언스(Alimera Sciences, Inc.)는 2022년 9월 23일, 재브 건강 연구 재단(Jaeb Center for Health Research Foundation Inc., JCHR)과 방사선 망막병증으로 인한 시력 손실 예방 관찰을 위해 플루오시놀론 아세토니드 유리체내 임플란트 또는 파리시맙 유리체내 주사를 비교 평가하는 무작위 임상 시험을 지원하고 제공하기 위한 계약을 발표했습니다.
노바티스 AG
개요: 노바티스는 다양한 의약품 및 제네릭 의약품의 발견, 개발, 제조 및 판매에 참여하고 있습니다. 이 회사는 전 세계적으로 혁신 의약품 부문과 바이오시밀러 및 제네릭 의약품 부문인 산도즈 부문의 두 가지 사업부를 운영하고 있습니다.
제품 포트폴리오:
듀레졸(Durezol): 안과 수술 및 내인성 전방 염증과 관련된 통증 및 염증 치료에 사용되는 국소 코르티코스테로이드입니다. 포도막염 치료.
주요 개발: 2022년 6월 17일, 제네릭 및 바이오시밀러 의약품 공급업체인 산도즈(Sandoz)는 유럽의약품청(EMA)이 자사의 바이오시밀러 하이리모즈(Hyrimoz, 아달리무맙) 고농도 제형에 대한 승인 신청을 접수했다고 발표했습니다. 해당 신청은 류마티스 관절염, 포도막염, 크론병, 궤양성 대장염, 건선 등 모든 적응증을 포함합니다.
글로벌 포도막염 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global uveitis market size was valued at US$ 456 million in 2022 and is estimated to reach US$ 837 million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).
Uveitis is an eye inflammation, which affects the middle layer of the tissue in the eyewall. The majority of the alter lie in the population ages of 20 to 50 years. Uveitis can sometimes be a serious issue that can also lead to loss of vision.
Market Dynamics
The major factors driving the global uveitis market are the rising demand for uveitis owing to increasing incidences of ophthalmic disorders such as uveitis glaucoma and uveitis cataract, surging awareness initiatives, advancements in technologies leading to the development of new drugs and novel product launches.
The increasing product pipeline of pharma companies and rising technological advancements leading to the development of new drugs are expected to drive the market’s growth.
The uveitis market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of ophthalmic disorders such as uveitis glaucoma, uveitis cataract, AMD and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.
The uveitis medications are used widely for treatment purpose. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce uveitis medication products such as eye drops, injections, pills or implants. The market for these medications is increasing worldwide due to the enhanced number of these ophthalmic disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market’s growth.
Various novel product launches, research studies, and rising awareness initiatives related to these uveitis medications contribute to the market’s growth. For instance, in November 1, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) which is a sustained release intravitreal implant indicated for non-infectious uveitis, via Medis Pharmaceutical Company, its distribution partner.
High cost associated with the treatment and high risk of side effects are expected to hamper the market’s growth.
Strict rules and regulations for the approval of medications utilized for uveitis is the major factor hindering the growth of the uveitis market. Various requirements, clinical trials must be fulfilled, leading to an increase in the overall cost of these medications. The high cost associated with these treatments is likely to hinder the growth.
High risk related to side effects of these medications is also limiting market’s growth. Market recalls are also a leading factor restraining the growth of the market. Several recalls are taking place due to leakage or complications in implants.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The uveitis market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in October 17, 2022, Kiora Pharmaceuticals, Inc. announced its results from KIO-100 (formerly PP-001) Phase 1 study, showing its potential for non-infectious uveitis, an ophthalmic inflammatory disease treatment.
Segment Analysis
The anterior uveitis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The anterior uveitis segment is the highest market holder in the global uveitis market. The global uveitis market is segmented based on disease type as anterior uveitis, intermediate uveitis, posterior uveitis and pan uveitis. The anterior uveitis segment is the largest market shareholder due to its increasing number of incidences globally, increasing technological advancements and novel product launches.
Anterior uveitis is the most common kind of uveitis which mostly affects the ciliary body and the inside of the front of eye (between the iris and the cornea). It is also also known as iritis. Anterior uveitis can be caused due to a trauma to the eye, like getting hit in the eye or having a foreign particle in the eye. It is also linked with common health problems including syphilis, rheumatoid arthritis, tuberculosis and viral (herpes simplex). Its symptoms include blurred vision, red or inflamed eye, small, irregular-shaped pupil and sensitivity to light.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market’s growth. For instance, in March 28, 2022, Bausch + Lomb, Bausch Health Companies’ eye health business and Clearside Biomedical, Inc. a biopharmaceutical company transforming the therapies’ delivery to the back of the eye via the suprachoroidal space (SCS) announced the commercial launch of XIPERE (triamcinolone acetonide injectable suspension) in U.S., the first therapy which got approval for suprachoroidal use by the U.S. Food and Drug Administration (FDA) for the macular edema associated with uveitis treatment.
Geographical Analysis
North America holds the largest market share in the global uveitis market.
North America dominates the global uveitis market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of uveitis medications in several ophthalmic conditions like uveitis glaucoma or uveitis cataract, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the uveitis market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in August 8, 2022, Clearside Biomedical, Inc., a biopharmaceutical company transforming the therapies’ delivery to the back of the eye via the suprachoroidal space (SCS), announced about entering into a sale agreement with HealthCare Royalty Partners.
Competitive Landscape
The uveitis market is highly competitive with local and global companies’ presence. Novartis Inc., AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in September 23, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced its agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), to support and provide ILUVIEN (fluocinolone acetonide intravitreal implant) intravitreal implant for “A randomized clinical trial evaluating fluocinolone acetonide intravitreal implants or intravitreal faricimab injections vs due to Radiation Retinopathy visual acuity loss prevention observation.
Novartis AG
Overview: Novartis is engaged in discovering, developing, manufacturing, and selling a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.
Product Portfolio:
Durezol: It is a topical corticosteroid which is indicated for pain and inflammation treatment linked with ocular surgery and endogenous anterior uveitis treatment.
Key Development: In June 17, 2022, Sandoz, a generic and biosimilar medicines provider, announced about application acceptance for high concentration formulation of its biosimilar Hyrimoz (adalimumab) by the European Medicines Agency (EMA) for regulatory review. The application covers all indications, including rheumatoid arthritis, uveitis, Crohn's disease, ulcerative colitis and plaque psoriasis
The global uveitis market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing product pipeline of pharma companies
4.1.1.2. Rising advancements in technologies leading to the development of new drugs
4.1.2. Restraints:
4.1.2.1. High cost associated with treatment
4.1.2.2. High risk of side effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Uveitis Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
7.1.2. Market Attractiveness Index, By Uveitis Type
7.2. Anterior Uveitis *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Intermediate Uveitis
7.4. Posterior Uveitis
7.5. Pan Uveitis
8. By Medications
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.2.3. Bethamethasone
8.2.4. Dexamethasone
8.2.5. Cortisone
8.2.6. Triamcinolone
8.2.7. Methylprednisolone
8.3. Anti-Rheumatic Drugs
8.3.1. Mycophenolate
8.3.2. Cyclosporine
8.3.3. Azathioprine
8.3.4. Tacrolimus
8.4. Cycloplegic-Mydriatic Drugs
8.4.1. Tropicamide
8.4.2. Cyclopentolate
8.4.3. Phenylephrine
8.4.4. Homatropine
8.4.5. Atropine
8.5. Immunomodulatory Therapy
8.5.1. Azathioprine
8.5.2. Methotrexate
8.5.3. Mycophenolate Mofetil
8.5.4. Cyclosporine
8.6. Biological Therapy
8.6.1. Infliximab
8.6.2. Adalimumab
8.6.3. Daclizumab
8.6.4. Interferon-Alfa
8.7. Anti-Viral Drugs
8.7.1. Aciclovir
8.7.2. Valaciclovir
8.8. Others
9. By Medication Form
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
9.1.2. Market Attractiveness Index, By Medication Form
9.2. Eye Drops *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Pills
9.4. Injections
9.5. Implants
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Novartis AG *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. AbbVie
13.3. Johnson & Johnson Services, Inc.
13.4. Amgen
13.5. Alimera Sciences
13.6. Bausch & Lomb Incorporated.
13.7. Kiora Pharmaceuticals, Inc.
13.8. Santen Pharmaceutical Co., Ltd.
13.9. EyePoint Pharmaceuticals, Inc.
13.10. Clearside Biomedical
LIST NOT EXHAUSTIVE
14. Global Uveitis Market – DataM
14.1. Appendix
14.2. About Us and Medications
14.3. Contact Us

언급된 주요 기업들

Novartis AG, AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical

표 목록 (Tables)

List of Tables

Table 1 Global Uveitis Market Value, By Uveitis Type, 2023, 2027 & 2031 ($ Million)

Table 2 Global Uveitis Market Value, By Medications, 2023, 2027 & 2031 ($ Million)

Table 3 Global Uveitis Market Value, By Medication Form, 2023, 2027 & 2031 ($ Million)

Table 4 Global Uveitis Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table 5 Global Uveitis Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 6 Global Uveitis Market Value, By Uveitis Type, 2023, 2027 & 2031 ($ Million)

Table 7 Global Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 8 Global Uveitis Market Value, By Medications, 2023, 2027 & 2031 ($ Million)

Table 9 Global Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 10 Global Uveitis Market Value, By Medication Form, 2023, 2027 & 2031 ($ Million)

Table 11 Global Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 12 Global Uveitis Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table 13 Global Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 14 Global Uveitis Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 15 Global Uveitis Market Value, By Region, 2022-2031 ($ Million)

Table 16 North America Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 17 North America Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 18 North America Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 19 North America Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 20 North America Uveitis Market Value, By Country, 2022-2031 ($ Million)

Table 21 South America Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 22 South America Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 23 South America Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 24 South America Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 25 South America Uveitis Market Value, By Country, 2022-2031 ($ Million)

Table 26 Europe Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 27 Europe Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 28 Europe Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 29 Europe Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 30 Europe Uveitis Market Value, By Country, 2022-2031 ($ Million)

Table 31 Asia-Pacific Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 32 Asia-Pacific Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 33 Asia-Pacific Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 34 Asia-Pacific Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 35 Asia-Pacific Uveitis Market Value, By Country, 2022-2031 ($ Million)

Table 36 Middle East & Africa Uveitis Market Value, By Uveitis Type, 2022-2031 ($ Million)

Table 37 Middle East & Africa Uveitis Market Value, By Medications, 2022-2031 ($ Million)

Table 38 Middle East & Africa Uveitis Market Value, By Medication Form, 2022-2031 ($ Million)

Table 39 Middle East & Africa Uveitis Market Value, By End-User, 2022-2031 ($ Million)

Table 40 Novartis AG: Overview

Table 41 Novartis AG: Product Portfolio

Table 42 Novartis AG: Key Developments

Table 43 AbbVie: Overview

Table 44 AbbVie: Product Portfolio

Table 45 AbbVie: Key Developments

Table 46 Johnson & Johnson Services, Inc.: Overview

Table 47 Johnson & Johnson Services, Inc.: Product Portfolio

Table 48 Johnson & Johnson Services, Inc.: Key Developments

Table 49 Amgen: Overview

Table 50 Amgen: Product Portfolio

Table 51 Amgen: Key Developments

Table 52 Alimera Sciences: Overview

Table 53 Alimera Sciences: Product Portfolio

Table 54 Alimera Sciences: Key Developments

Table 55 Bausch & Lomb Incorporated.: Overview

Table 56 Bausch & Lomb Incorporated.: Product Portfolio

Table 57 Bausch & Lomb Incorporated.: Key Developments

Table 58 Kiora Pharmaceuticals, Inc.: Overview

Table 59 Kiora Pharmaceuticals, Inc.: Product Portfolio

Table 60 Kiora Pharmaceuticals, Inc.: Key Developments

Table 61 Santen Pharmaceutical Co., Ltd.: Overview

Table 62 Santen Pharmaceutical Co., Ltd.: Product Portfolio

Table 63 Santen Pharmaceutical Co., Ltd.: Key Developments

Table 64 EyePoint Pharmaceuticals, Inc.: Overview

Table 65 EyePoint Pharmaceuticals, Inc.: Product Portfolio

Table 66 EyePoint Pharmaceuticals, Inc.: Key Developments

Table 67 Clearside Biomedical: Overview

Table 68 Clearside Biomedical: Product Portfolio

Table 69 Clearside Biomedical: Key Development

그림 목록 (Figures)

List of Figures

Figure 1 Global Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 2 Global Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 3 Global Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 4 Global Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 5 Global Uveitis Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 7 Global Uveitis Market Y-o-Y Growth, By Uveitis Type, 2022-2031 (%)

Figure 8 Anterior Uveitis: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 9 Intermediate Uveitis: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 10 Posterior Uveitis: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 11 Pan Uveitis: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 12 Global Uveitis Market Y-o-Y Growth, By Medications, 2022-2031 (%)

Figure 13 Corticosteroids: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 14 Anti-Rheumatic Drugs: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 15 Cycloplegic-Mydriatic Drugs: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 16 Immunomodulatory Therapy: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 17 Biological Therapy: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 18 Anti-Viral Drugs: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 19 Others: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 20 Global Uveitis Market Y-o-Y Growth, By Medication Form, 2022-2031 (%)

Figure 21 Eye Drops: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 22 Pills: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 23 Injections: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 24 Implants: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 25 Global Uveitis Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 26 Hospital Pharmacies: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 27 Retail Pharmacies: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 28 Online Pharmacies: Global Uveitis Market Value, 2022-2031 ($ Million)

Figure 29 Global Uveitis Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 30 North America Uveitis Market Value, 2022-2031 ($ Million)

Figure 31 North America Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 32 North America Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 33 North America Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 34 North America Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 35 North America Uveitis Market Share, By Country, 2022 & 2031 (%)

Figure 36 South America Uveitis Market Value, 2022-2031 ($ Million)

Figure 37 South America Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 38 South America Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 39 South America Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 40 South America Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 41 South America Uveitis Market Share, By Country, 2022 & 2031 (%)

Figure 42 Europe Uveitis Market Value, 2022-2031 ($ Million)

Figure 43 Europe Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 44 Europe Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 45 Europe Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 46 Europe Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 47 Europe Uveitis Market Share, By Country, 2022 & 2031 (%)

Figure 48 Asia-Pacific Uveitis Market Value, 2022-2031 ($ Million)

Figure 49 Asia-Pacific Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 50 Asia-Pacific Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 51 Asia-Pacific Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 52 Asia-Pacific Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 53 Asia-Pacific Uveitis Market Share, By Country, 2022 & 2031 (%)

Figure 54 Middle East & Africa Uveitis Market Value, 2022-2031 ($ Million)

Figure 55 Middle East & Africa Uveitis Market Share, By Uveitis Type, 2022 & 2031 (%)

Figure 56 Middle East & Africa Uveitis Market Share, By Medications, 2022 & 2031 (%)

Figure 57 Middle East & Africa Uveitis Market Share, By Medication Form, 2022 & 2031 (%)

Figure 58 Middle East & Africa Uveitis Market Share, By End-User, 2022 & 2031 (%)

Figure 59 Novartis AG: Financials

Figure 60 AbbVie: Financials

Figure 61 Johnson & Johnson Services, Inc.: Financials

Figure 62 Amgen: Financials

Figure 63 Alimera Sciences: Financials

Figure 64 Bausch & Lomb Incorporated.: Financials

Figure 65 Kiora Pharmaceuticals, Inc.: Financials

Figure 66 Santen Pharmaceutical Co., Ltd.: Financials

Figure 67 EyePoint Pharmaceuticals, Inc.: Financials

Figure 68 Clearside Biomedical: Financials

세계의 포도막염 시장(2023-2030년)

Global Uveitis Market - 2023-2030